drugset

drugset / Trial / NCT07404111

A Study of VV-14305 for the Treatment of Thyroid Eye Disease

NCT07404111 ↗

Phase 1/2 Not yet recruiting 110 enrolled Kriya Therapeutics, Inc.

RandomizedSequentialDouble-blindTreatment

Summary

The goal of this study is to evaluate the safety, tolerability, and efficacy of KRIYA-586 (VV-14305) in treating thyroid eye disease (TED).

Timeline

Start: 2026-02
Primary completion: 2028-02
Completion: 2029-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VV-14305	Unknown	—	Other

Indications